Newsfiscal.ai
DiaMedica Therapeutics Reaches Patient Enrollment Milestone for Phase 2/3 Trial of DM199 in Acute Ischemic Stroke
· Published
Article summary
DiaMedica Therapeutics has successfully enrolled the 200th patient in its Phase 2/3 clinical trial of DM199 for the treatment of acute ischemic stroke, triggering a planned interim analysis.
An excerpt from the original article.
Comments —
Loading comments…